Compliance Challenges in India: Why Your Program May Not Translate: Part 2
09 September 2016
Partner David Simon was featured in a Compliance & Ethics article, “Compliance Challenges in India: Why Your Program May Not Translate: Part 2.” The article previewed an upcoming Compliance & Ethics Institute session, where Simon is featured as a panelist, and walked through a scenario of a company’s India market strategy involving independent sales representatives allegedly taking bribes. Simon provided insight and recommended next steps from an outside counsel perspective. He said, “I would likely recommend pulling and reviewing all related government sales contracts, conducting a forensic accounting review of the payments associated with them and conducting interviews of the sales representative himself and any involved employees in an attempt to identify inappropriate payments or improper influence.”
To read more about part 1, click here.
To read more about part 1, click here.
Author(s)
Related Insights
21 March 2025
IP Litigation Current
Federal Circuit Opens the Door to Additional Domestic Industry Investment: “Ordinary Importer” No Longer
In its recent decision in Lashify, Inc. v. International Trade Commission, the Federal Circuit opened the door for patent owners to include expanded categories of domestic investment to satisfy the economic prong of the domestic industry requirement under Section 337(a)(3)(B).
21 March 2025
Manufacturing Industry Advisor
Federal Court Rejects FCA’s “65%-100%” Language as Insufficient to Constitute the Necessary Quantity Term in a Requirements Contract—A Win for Suppliers
A recent federal court decision marks an important win for automotive suppliers in the ongoing debate over what constitutes a valid requirements contract under Michigan law following the Michigan Supreme Court’s decision in MSSN, Inc. v. Airboss Flexible Products Co. (2023).
27 April 2025
Events
Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value
Foley partner Kinal Patel is speaking at the 2025 National Proton Conference in a panel titled “Innovative Payment Strategies in Proton Therapy: Addressing Challenges and Driving Value” on April 27.